Gene expression profiling offers insights into the role of innate immune signaling in SSc

Seminars in Immunopathology

Volumn 37, Issue 5, 2015, Pages 501-509

  Johnson, Michael E ^a   Pioli, Patricia A ^a   Whitfield, Michael L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DISEASE MODEL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOREGULATION; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SKIN; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; GENETICS; IMMUNOLOGY; INFLAMMATION;

GENE EXPRESSION PROFILING; HUMANS; IMMUNITY, INNATE; INFLAMMATION; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN;

EID: 84940900206     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-015-0512-6     Document Type: Review

References (65)

1. Milano A et al (2008) Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 3:e2696
2. Pendergrass SA, Lemaire R, Francis IP, Mahoney JM, Lafyatis R, Whitfield ML (2012) Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol 132:1363–1373
3. Hinchcliff M et al (2013) Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol 133:1979–1989
4. Mahoney JM et al (2015) Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. PLoS Comput Biol 11:e1004005
5. Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM, Feghali-Bostwick CA (2011) Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 63:783–794
6. Christmann RB et al (2014) Association of interferon- and transforming growth factor beta-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheumatol 66:714–725
7. Whitfield ML et al (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 100:12319–12324
8. Gardner H et al (2006) Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 54:1961–1973
9. Perou CM et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752
10. Alizadeh AA et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511
11. Garber ME et al (2001) Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 98:13784–13789
12. Bhattacharjee A et al (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 98:13790–13795
13. Sorlie T et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418–8423
14. Lafyatis R et al (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60:578–583
15. Chakravarty EF et al (2015). A pilot randomized placebo-controlled study of abatacept for the treatment of diffuse cutaneous systemic sclerosis. Arthritis Res Ther. In press.
16. Gordon JK et al (2015). Nilotinib in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis Res Ther. Submitted.
17. Assassi S et al (2015). Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis. Arthritis Rheum. In Press.
18. Wong AK, Park CY, Greene CS, Bongo LA, Guan Y, Troyanskaya OG (2012) IMP: a multi-species functional genomics portal for integration, visualization and prediction of protein functions and networks. Nucleic Acids Res 40:W484–W490
19. Assassi S, Radstake TR, Mayes MD, Martin J (2013) Genetics of scleroderma: implications for personalized medicine? BMC Med 11:9
20. Taroni J et al (2015). Genome-wide gene expression analysis of systemic sclerosis esophageal biopsies identifies disease-specific molecular subsets. Arthritis Res Ther. In press.
21. Chung L et al (2009) Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 60:584–591
22. Sargent JL et al (2009) A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 130:694–705
23. Greenblatt MB et al (2012) Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol 180:1080–1094
24. Johnson ME et al (2015) Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts. PLoS One 10:e0114017
25. Bhattacharyya S, Wei J, Tourtellotte WG, Hinchcliff M, Gottardi CG, Varga J (2012) Fibrosis in systemic sclerosis: common and unique pathobiology. Fibrogenesis Tissue Repair 5:S18
26. Farina A et al (2014) Epstein-Barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in scleroderma. J Invest Dermatol 134:954–964
27. van Bon L et al (2010) Distinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 69:1539–1547
28. Artlett CM, Sassi-Gaha S, Rieger JL, Boesteanu AC, Feghali-Bostwick CA, Katsikis PD (2011) The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum 63:3563–3574
29. Arron ST et al (2014) High Rhodotorula sequences in skin transcriptome of patients with diffuse systemic sclerosis. J Invest Dermatol 134:2138–2145
30. Christmann RB et al (2011) Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Rheum 63:1718–1728
31. Mathes AL et al (2014) Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin. Ann Rheum Dis 73:1864–1872
32. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8:958–969
33. Higashi-Kuwata N et al (2010) Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther 12:R128
34. Atamas SP, White B (2003) Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev 14:537–550
35. Chen ZY et al (1984) Immune complexes and antinuclear, antinucleolar, and anticentromere antibodies in scleroderma. J Am Acad Dermatol 11:461–467
36. Seibold JR, Medsger TA Jr, Winkelstein A, Kelly RH, Rodnan GP (1982) Immune complexes in progressive systemic sclerosis (scleroderma). Arthritis Rheum 25:1167–1173
37. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24:328–332
38. Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. Faseb J 18:816–827
39. Varga J, Pasche B (2009) Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 5:200–206
40. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3:23–35
41. Li MO, Sanjabi S, Flavell RA (2006) Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25:455–471
42. Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V (2011) Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol 29:163–183
43. Assassi S et al (2010) Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum 62:589–598
44. Eloranta ML et al (2010) Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 69:1396–1402
45. Kim D et al (2008) Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum 58:2163–2173
46. van Bon L et al (2014) Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. NEJM 370:433–443
47. Luzina IG, Atamas SP, Wise R, Wigley FM, Xiao HQ, White B (2002) Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol 26:549–557
48. Falanga V, Gerhardt CO, Dasch JR, Takehara K, Ksander GA (1992) Skin distribution and differential expression of transforming growth factor β1 and β2. J Dermatol Sci 3:131–136
49. Sfikakis PP, McCune BK, Tsokos M, Aroni K, Vayiopoulos G, Tsokos GC (1993) Immunohistological demonstration of transforming growth factor-β isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol 69:199–204
50. Higashi-Kuwata N, Makino T, Inoue Y, Takeya M, Ihn H (2009) Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma. Exp Dermatol 18:727–729
51. Pechkovsky DV et al (2010) Alternatively activated alveolar macrophages in pulmonary fibrosis—mediator production and intracellular signal transduction. Clin Immunol 137:89–101
52. Truchetet M-E, Brembilla NC, Montanari E, Allanore Y, Chizzolini C (2011) Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arth Res Ther 13:R166
53. Kessel A et al (2004) Increased CD8+ T cell apoptosis in scleroderma is associated with low levels of NF-kappa B. J Clin Immunol 24:30–36
54. Mathian A et al (2012) Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis 71:1227–1234
55. Murata M et al (2008) Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci 50:240–242
56. Radstake TR et al (2009) The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFβ and IFNγ distinguishes SSc phenotypes. PLoS One 4:e5903
57. Rodríguez-Reyna TS et al (2012) Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int 32:2653–2660
58. Deleuran B, Abraham DJ (2007) Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma. Nat Clin Pract Rheum 3:682–683
59. Axtell RC, Raman C (2012) Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev 248:23–35
60. Brand S (2009) Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut 58:1152–1167
61. Camporeale A (2012) IL-6, IL-17, and STAT3: a holy trinity in auto-immunity? Front Biosci 17:2306–2326
62. Kimura A, Kishimoto T (2011) Th17 cells in inflammation. Int Immunopharmacol 11:319–322
63. Zheng SG (2013) Regulatory T cells versus Th17: differentiation of Th17 versus Treg, are they mutually exclusive? In: IL-17, IL-22 and their producing cells: role in inflammation and autoimmunity: springer., pp 91–107
64. Steinman L (2007) A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med 13:139–145
65. Marangoni RG et al (2015) Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors. Arthritis Rheumatol 67:1062–1073